🇺🇸 FDA
Patent

US 8227417

HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants

granted A61KA61K2039/53A61K2039/55516

Quick answer

US patent 8227417 (HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jul 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jul 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61K, A61K2039/53, A61K2039/55516, A61K2039/57, A61K38/1709